Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...

On Jan. 30, the U.S. Food and Drug Administration (FDA) approved a new drug called suzetrigine to treat moderate-to-severe pain. The prescription pills, sold under the brand name Journavx and made ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).

Journavx (suzetrigine) is a new nonopioid medication manufactured by Vertex Pharmaceuticals to help treat and manage moderate to severe acute pain. While opioids work by attaching to special ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain medicine in the US in more than 20 years. The oral NaV1.8 inhibitor has been ...

Medscape News Slideshows, January 31, 2025 Alert FDA OKs First-In-Class Nonopioid Pain Med Suzetrigine Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous ...

Nature, online article titled: US drug agency approves potent painkiller the first non-opioid in decades. The FDA's nod for suzetrigine bolsters confidence in the pharmaceutical industry's strategy to ...